Contents lists available at ScienceDirect



Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl



Scaffold-based design and synthesis of potent N-type calcium channel blockers

Gerald W. Zamponi^a, Zhong-Ping Feng^{a,†}, Lingyun Zhang^b, Hossein Pajouhesh^b, Yanbing Ding^b, Francesco Belardetti^b, Hassan Pajouhesh^b, David Dolphin^c, Lester A. Mitscher^d, Terrance P. Snutch^{e,*}

^a Department of Physiology and Pharmacology, University of Calgary, Calgary, Alberta, Canada

^b Neuromed Pharmaceuticals Ltd, 301-2389 Health Sciences Mall, Vancouver, BC, Canada

^c Department of Chemistry, University of British Columbia, Vancouver, BC, Canada

^d Department of Medicinal Chemistry, University of Kansas, Lawrence, KS, USA

^e Michael Smith Laboratories, University of British Columbia, Vancouver, BC, Canada

ARTICLE INFO

Article history: Received 31 December 2008 Revised 1 September 2009 Accepted 4 September 2009 Available online 11 September 2009

Keywords: Calcium channel blocker N-type Pain Diphenylmethylpiperazine

ABSTRACT

The therapeutic agents flunarizine and lomerizine exhibit inhibitory activities against a variety of ion channels and neurotransmitter receptors. We have optimized their scaffolds to obtain more selective N-type calcium channel blockers. During this optimization, we discovered **NP118809** and **NP078585**, two potent N-type calcium channel blockers which have good selectivity over L-type calcium channels. Upon intraperitoneal administration both compounds exhibit analgesic activity in a rodent model of inflammatory pain. **NP118809** further exhibits a number of favorable preclinical characteristics as they relate to overall pharmacokinetics and minimal off-target activity including the hERG potassium channel. © 2009 Elsevier Ltd. All rights reserved.

Voltage-gated ion channel blockers are attractive drug targets for an expanding range of therapeutic indications.¹ Voltage-dependent calcium channels play a central role in the control of cellular excitability and a number of calcium-dependent cellular functions, including gene transcription and neurotransmitter release.² Biophysical and pharmacological studies have identified four subtypes of high voltage activated (HVA) calcium channels that are encoded by a family of seven different α_1 subunit proteins (Ca_v): L-type (Ca_v1.1-Ca_v1.4), N-type (Ca_v2.2), P/Q-type (Ca_v2.1) and R-type (Ca_v2.3) as well as low voltage activated calcium channels, called T-type, encoded by three distinct α_1 subunit proteins (Ca_v3.1– Ca_v3.3).³ A subset of the HVA calcium channels are located at the presynaptic termini of neurons, where they are directly involved in the regulation of neurotransmitter release. Of particular interest, the transmission of pain signals from periphery to the central nervous system is mediated by N-type channels located at primary afferent terminals in the dorsal horn of the spinal cord.⁴

Over the last decade, synthetic efforts have focused on development of both peptidic and non-peptidic based small molecule Ntype calcium channel blockers for analgesia or neuroprotection.⁵ This work was encouraged by positive clinical observations for the N-type channel blocking peptide drug, Prialt[™] (SNX-111, ziconotide[®]), although the market for Ziconotide[®] is limited by the requirement for intrathecal delivery.⁶

The objective of the current drug discovery program was the identification of orally active, selective N-type blockers with an acceptable therapeutic index aimed at the treatment of chronic/ inflammatory pain. Both flunarizine⁷ and lomerizine⁸ possess diphenylmethylpiperazine moieties as the basic skeleton (Fig. 1) and initial structure–activity relationship (SAR) investigations indicated that this backbone contributed to calcium channel blocking activities. In the present report we investigated the structural requirements for selective N-type calcium channel blockade around the flunarizine and lomerizine backbones. Antagonist activity was measured in HEK293 cells transiently transfected with rat



Figure 1. Structures of flunarizine and lomerizine.

^{*} Corresponding author. Tel.: +1 604 822 6968; fax: +1 604 822 6470. *E-mail address*: snutch@msl.ubc.ca (T.P. Snutch).

[†] Present address: Department of Physiology, University of Toronto, Toronto, Ontario, Canada.

⁰⁹⁶⁰⁻⁸⁹⁴X/ $\$ - see front matter \odot 2009 Elsevier Ltd. All rights reserved. doi:10.1016/j.bmcl.2009.09.008

brain calcium channel subunits cDNAs (N-type: $\alpha_{1B} + \alpha_2\delta - 1 + \beta_{1b}$ subunits; L-type: $\alpha_{1C} + \alpha_2\delta - 1 + \beta_{1b}$ subunits). After incubation for 24–72 h, whole cell current recordings were performed with barium as the charge carrier as previously described.⁹ Currents were typically elicited from a holding potential of -100 mV to the peak of current–voltage relation for each channel type. For each calcium channel subtype each compound was examined for blockade by patch clamp analysis on between 3 and 5 cells.

We began by testing the potency of flunarizine and lomerizine against the cloned N-type calcium channel exogenously expressed in HEK cells and found that they both potently inhibited functional N-type channels (estimated IC₅₀ values of 0.08 and 0.09 μ M, respectively; Table 1). However, their inhibitory activities against L-type channels was also high, providing only a 1.7–3.9-fold ratio of selectivity over the two types of high voltage-activated calcium channels (Table 1). A major direction of the SAR optimization was to decrease L-type activity while maintaining the high affinity for N-type calcium channel blockade.

We hypothesized that the benzhydrylpiperazine and trimethoxybenzylpiperazine moieties, respectively, could be acting as selectivity elements. With this in mind, we designed and synthesized a series of compounds replacing the cinnamyl portion in flunarizine. We first examined the effect of the methylene spacer between the piperazine and the benzhydryl group (Table 2). Further, we investigated the effect on N-type calcium channel activity and selectivity by changing the amine into an amide (Table 3). The SAR studies of these chemical series were guided by the whole cell patch clamp analysis of the functional blockade of N-type and Ltype channels expressed in HEK cells.

Table 2 shows that the benzhydrylpiperazine backbone with a benzhydryl group on the right hand side resulted in compounds with a significantly poorer degree of N-type blockade (compounds **1a–1e**) compared with either parent compounds. Varying the length of the linker between the benzhydryl and the piperazine core resulted in a 10-fold range of N-type affinities suggesting that linker length nonetheless contributed to N-type blocking affinity.

Table 1

Blocking activities of flunarizine and lomerizine against N-type and L-type calcium channels

Compound	N-type Est. IC ₅₀ (µM)	L-type Est. IC ₅₀ (µM)	L/N ratio
Flunarizine	0.08	0.31	3.9
Lomerizine	0.09	0.15	1.7

Table 2

N-type calcium channel blocking activities for compounds 1a-1e



Compound	n	N-type Est. IC ₅₀ (μM)
1a	0	>50
1b	1	5
1c	2	6
1d	3	20
1e	4	50

Table 3

N-type and L-type calcium channel blocking activities for compounds 2a-2e



Compound	n	N-type Est. IC ₅₀ (μM)	L-type Est. IC ₅₀ (µM)	L/N ratio
2a 2b (NP118809) 2c 2d	0 1 2 3	>50 0.11 23 >50	NA 12.2 NA NA	 111
2e	4	50	NA	_

Table 3 shows that the introduction of an amide into the right hand linker was also generally unfavorable compared to the parent compounds. A notable exception to this was compound **2b** (**NP118809**; see Scheme 1) with a total linker length of 3 carbons (n = 1) and which exhibited approximately a 500-fold increased N-type channel blockade compared to compounds in this series with linkers either shorter (n = 0, 2a) or longer (n = 2-4, (2c-e)). Examination of the effect of **NP118809** on functional L-type calcium channel activity showed that this compound was approximately 111-fold more selective for N-type channels.

To probe the effect of bioisosteric replacement of carbon on the **NP118809** linker, we examined the bioisosteric potential of 3,3diphenylpropan-1-one bound to the piperazine core, while maintaining the benzhydryl moiety on the opposite side of molecule (Scheme 2). This modification allowed the maximum conservation of the polarity and geometry of the **NP118809** (Table 4). While compound **3a** maintained favorable inhibitory activity for N-type channels (est. $IC_{50} = 0.15 \mu$ M) compared to that of **NP118809**, the N-type:L-type selectivity profile was significantly lower (12-fold). Further exploration on the linker with compounds **3b**-**3c** showed a trend toward decreased N-type channel blocking affinity (Table 4).

Examination of a series of derivatives focused around the lomerizine-based trimethoxybenzylpiperazine moiety resulted in compounds with a generally high degree of N-type channel block-ade. Unlike that for the flunarizine-based series, a longer linker to the benzhydryl group (six carbons total length) did not seem to be deleterious. Furthermore, there was little change in N-type affinity regardless of whether an amide was included in the linker on either side of the piperazine core (Tables 5 and 6). In particular, compound **4a** (**NP078585**; see Scheme 1) exhibited potent N-type channel functional blockade (est. $IC_{50} = 0.11 \mu$ M). Examination of the effect of **NP078585** on L-type calcium channels showed that this compound was approximately 25-fold more selective for N-type channels (Table 5).

Replacement of the trimethoxybenzyl with cinnamyl moiety was studied without changing the chain linker lengths (Table 6). Compound **5a** had the closest N-type potency compared to **NP078585** (est. $IC_{50} = 0.05 \ \mu\text{M}$) but possessed a lower selectivity ratio of L-type to N-type blockade (~7.8-fold). The other derivatives in this series all exhibited sub-micromolar N-type channel affinities but again with no improvement over **NP078585** in the L-type to N-type selectivity ratio (Table 6).

The two compounds demonstrating high affinity for the N-type channel together with the best selectivity over L-type calcium channels were selected for pharmacokinetic profiling. Examination of pharmacokinetics and oral bioavailability showed that in rats **NP078585** was absorbed relatively rapidly ($T_{max} = 1.0$ h), elimi-



NP078585

Scheme 1. Reagents and conditions: (a) PPh₃, CH₃CN, reflux; (b) LiHMDS, -78 °C, benzophenone; (c) MeOH, H₂, 5% Pd/C, 50 psi; (d) Boc-piperazine, EDC; (e) 25% TFA, 3,4,5-trimethoxybenzoylchloride, K₂CO₃; (f) LiAlH₄, THF.



Cmpd 3a

Scheme 2. Reagents and conditions: (a) diphenylmethyl isocyanate, rt; (b) 2-bromo-N,N-diphenylacetamide, NaHCO₃, CH₃CN, reflux; (c) 2-(diphenylamino)acetic acid, EDC, DMAP.

Table 4

N-type and L-type calcium channel blocking activities for compounds 3a-3c



Compound	Х	Y	Z	N-type Est. IC ₅₀ (µM)	L-type Est. IC ₅₀ (µM)	L/N ratio
3a	CO	NH	CH	0.15	1.84	12
3b	CO	CH	N	6.61	NA	
3c	CH	CO	N	0.26	NA	

Table 5

N-type and L-type calcium channel blocking activities for compounds 4a-4c



Compound	Y	Х	N-type Est. IC ₅₀ (µM)	L-type Est. IC ₅₀ (µM)	L/N ratio
4a (NP078585)	H	Н	0.11	2.8	12
4b	O	О	0.54	NA	
4c	H	О	0.19	NA	

nated moderately slowly ($t_{1/2}$ = 4.5 h) and possessed an oral bioavailability of 20% (Table 7). The mean volume of distribution for **NP078585** following intravenous administration (11,693 ml/kg) was in excess of the calculated total body water in the rat suggesting that **NP078585** was widely distributed outside of plasma and/ or bound to plasma proteins. **NP118809** exhibited both acceptable absorption (T_{max} = 2.3 h) and half-life ($t_{1/2}$ = 2.1 h) characteristics and a mean oral bioavailability of 30%. Similar to that for **NP078585**, the volume of distribution of **NP118809** (5787 ml/kg)

Table 6

N-type and L-type calcium channel blocking activities for compounds 5a-5h



was suggestive of a high degree of protein binding and/or distribution outside of plasma.

Based upon their combined in vitro and pharmacokinetic properties **NP078585** and **NP118809** were subject to in vivo assay in the rat formalin model inflammatory pain.¹⁰ Figure 2 shows that upon intraperitoneal (ip) administration both **NP118809** and **NP078585** (25 mg/kg) both exhibited significant analgesic activity in the phase IIA portions of the rat formalin model.

In order to further refine the preclinical profiles of the two candidate molecules their off-target interactions with the hERG potassium channel was examined by whole cell patch clamp analysis of HEK cells stably expressing hERG. A single 1 μ M dose application of **NP078585** was found to significantly block hERG currents (98.7 ± 0.2%, *n* = 3) suggesting the potential for cardiovascular liability for this agent. Contrastingly, an initial single test dose test of **NP118809** (1 μ M) resulted in only partial blockade of hERG currents (24.8 ± 0.3%, *n* = 3). Subsequently, a dose–response profile on hERG tail currents was determined for **NP118809**. Figure 3 shows the estimated IC₅₀ of **NP118809** for the hERG channel extrapolated from the concentration-dependent inhibition curve = 7.4 μ M. As such, **NP118809** would not be considered a potent blocker of the hERG potassium channel.

Further examining NP118809 at a concentration of 10 µM for off-target activity using a radioligand binding displacement screen of 112 ion channel, receptor and other signaling targets (MDS Pharma Services; http://discovery.mdsps.com) resulted in >50% displacement of radioligand from only four targets: L-type calcium channel, cannabinoid CB₁, µ opiate receptor and voltage-gated sodium channel. Subsequent secondary screens for possible functional interactions against these targets by NP118809 using representative tissue assays (MDS Pharma Services) showed no significant agonism or antagonism (>50%) at a higher test concentration of 30 µM. That there was no observed physiological effect of NP118809 on L-type channel function in a guinea pig model of atrial inotropy while we determined an $IC_{50} \sim 12 \ \mu M$ against the L-type channel by electrophysiological assessment is likely reflective of the highly state-dependent nature of **NP118809** channel blockade (data not shown). Voltage- and frequency-dependent blockade would favor drug interaction with a subset of channels under native conditions and are predicted to be important factors towards maximizing the therapeutic window of ion channel blockers in vivo.¹¹

In summary, SAR studies around the flunarizine and lomerizine diphenylmethylpiperazine backbones produced a series of high

				~		
Compound	Y	х	R	N-type Est. IC ₅₀ (µM)	L-type Est. IC ₅₀ (µM)	L/N ratio
5a	Н	Н	Н	0.05	0.39	8
5b	Н	p-F	Н	0.09	0.12	1.3
5c	Н	Н	Н	0.12	0.33	2.8
5d	Н	Н	<i>p</i> -Methoxy	0.19	NA	-
5e	0	Н	<i>p</i> -Methoxy	0.09	0.25	2.8
5f	Н	Н	1,3-Dioxole	0.19	NA	_
5g	0	Н	1,3-Dioxole	0.13	0.74	5.7
5h	0	Н	p-Amino	0.15	0.83	5.5

Table 7	
Mean pharmacokinetic parameters in rat plasma following single oral or intravenous dosing for NP078585 and NP118809	

Compound/route	Dose (mg/kg)	C _{max} (ng/ml)	$T_{\max}(\mathbf{h})$	$AUC_{(0-8)}$ (ng h/ml)	$AUC_{(i)}$ (ng h/ml)	$t_{1/2}(h)$	$V_{\rm dss}~({\rm ml/kg})$	CL/F (ml/h kg)	F (%)
NP078585 intravenous	2	462 (182)	NA	725 (104)	975 (192)	5.0 (1.1)	11693 (1360)	2111 (449)	NA
NP078585 oral	10	173 (64)	1.0 (0.0)	753 (292)	1021 (269)	4.5 (2.0)	NA	10204 (2331)	21 (5.5)
NP118809 intravenous	2	771 (95)	NA	715 (171)	761 (169)	3.3 (1.2)	5787 (2345)	2730 (680)	NA
NP118809 oral	10	235 (94)	2.3 (1.5)	999 (386)	1136 (469)	2.1 (0.5)	NA	9868 (3969)	30 (12.3)

Data are presented as mean (standard error in brackets).

AUC(0-8): Area under the plasma concentration versus time curve from time zero to 8 h post-dose.

AUC(i): Area under the plasma concentration versus time curve from time zero to infinity.

 C_{\max} : The highest observable concentration.

 T_{\max} : Time to C_{\max} .

CL/F: Plasma clearance.

 $V_{\rm dss}$: Apparent volume of distribution.

 $t_{1/2}$: Terminal elimination half-life.

F: Oral bioavailability.

NA: Not applicable.



Figure 2. Efficacy of **NP078585** and **NP118809** in the rat formalin model of inflammatory pain. Compounds were administered at a dose of 25 mg/kg ip **NP078585** *n* = 26 animals, **NP118809** *n* = 24 animals. Statistical significance ^{*}*p* < 0.01; ^{***}*p* < 0.001.



Figure 3. Concentration-dependent inhibition of the hERG potassium channel by **NP118809**. (A) hERG tail currents recorded in the presence of 0.1% DMSO (control) and after application of 3 μ M NP118809. Inset shows the rate of inhibition of the tail current by 3 μ M NP118809 from the same cell. (B) Concentration-dependent inhibition of the peak hERG channel tail currents by **NP118809**. The concentration-dependent inhibition curve was generated by using the mean data obtained for 0.1, 1, 3 and 10 μ M NP118809 (solid line) and extrapolated to 100% inhibition (dash line). Data are the mean of 4 values ± standard error for each concentration applied. Data was analyzed and fitted using OriginPro v.7 software. To obtain the IC₅₀ and Hill slope coefficient ($n_{\rm H}$) the concentration–response curve was fitted with a logistic equation of:

$$y = \max\left[1 - \frac{1}{1 + \left(\frac{\mathrm{drug}}{\mathrm{IC}_{50}}\right)^{n_{\mathrm{H}}}}\right]$$

affinity N-type calcium channel blockers (<200 nM IC_{50} s) that exhibit a significant degree of selectivity (25–111-fold) over the closely related L-type channel. **NP078585** and **NP118809** were discovered as N-type calcium channel antagonists that exhibit strong analge-

sic activity in an inflammatory rat model. Both compounds exhibit suitable pharmacokinetic characteristics for animal testing although **NP118809** appears to be the more favorable preclinical candidate based upon its lower off-target affinity to the hERG potassium channel and lack of significant interaction against 112 additional molecular targets. Some relevant experimental details have already been published in another form.¹²

Acknowledgments

Work in the laboratories of T.P.S. and G.W.Z. is supported by the Canadian Institutes of Health Research. T.P.S. a Canada Research Chair in Biotechnology and Genomics-Neurobiology. G.W.Z. is a Scientist of the Alberta Heritage Foundation for Medical Research and is also supported by a Canada Research Chair in Molecular Neurobiology.

References and notes

- 1. Gribkoff, V. K.; Starrett, J. E. Expert Opin. Pharmacother. 1999, 1, 61.
- Calterall, W. A. Annu. Rev. Cell Dev. Biol. 2000, 16, 521; (b) Cox, B.; Denyer, J. C. Expert Opin. Ther. Patents 1998, 8, 1237; (c) Elmsile, K. S. J. Neurosci. Res. 2004, 75, 733.

- Snutch, T. P.; Peloquin, J.; Mathews, E.; McRory, J. Molecular Properties of Voltage-Gated Calcium Channels. In *Voltage-Gated Calcium*; Zamponi, G., Ed.; Landes Bioscience, 2005; pp 61–94.
- (a) Kerr, L. M. et al *Eur. J. Pharmacol.* **1998**, *146*, 181; (b) Dubel, S. J. et al *Proc. Natl. Acad. Sci. U.S.A.* **1992**, *89*, 5058; (c) Westenbroek, R. E. et al *Neuron* **1992**, *9*, 1099; (d) Dunlap, K.; Luebke, J. I.; Turner, T. J. *Trends Neurosci.* **1995**, *18*, 89.
- (a) Hu, L.-Y. et al Bioorg. Med. Chem. Lett. 1999, 9, 907; (b) Hu, L.-Y. et al Bioorg. Med. Chem. Lett. 1999, 9, 1121; (c) Knutsen, L. J. S. et al Bioorg. Med. Chem. Lett. 2007, 17, 662; (d) Shoji, Masataka et al Bioorg. Med. Chem. Lett. 2006, 14, 5333.
- (a) Staats, P. S. et al J. Am. Med. Assoc. 2004, 291, 63; (b) Jain, K. K. Expert Opin. Invest. Drugs 2000, 9, 2403; (c) Bowersox, S.; Tich, N.; Mayo, M.; Luther, R. Drugs Future 1998, 23, 152.
- (a) Cohan, S. L.; Redmond, D. J.; Chen, M.; Wilson, D.; Cyr, P. J. Cereb. Blood Flow Metab. **1993**, *13*, 947; (b) Pauwels, P. J.; Leysen, J. E.; Janssen, P. A. J. Life Sci. **1991**, *48*, 1881.
- 8. Hara, H.; Morita, T.; Sukamoto, T.; Cutrer, F. M. CNS Drug Rev. 1995, 1, 204.
- 9. Bourinet, E. et al Nature Neurosci. 1999, 2, 407.
- (a) Dubuisson, D.; Dennis, S. G. Pain **1977**, *4*, 161; (b) Malmberg, A. B.; Yaksh, T. L. J. Neurosci. **1994**, 14, 4882.
- 11. Snutch, T. P. NeuroRx 2005, 2, 662.
- Snutch, T. P.; Zamponi, G. W. U.S. Patent, 7,064, 128 B2, 2006.; Snutch, T.P. U.S. Patent 6,387,897, 2002.